
CURRICULUM VITAE

Mario Nuvolone, M.D. Ph.D.

Email: mario.nuvolone@unipv.it

Current position

Associate Professor in Clinical Chemistry and Clinical Molecular Biology

Department of Molecular Medicine, University of Pavia

(Habilitation as Full Professor in Clinical Chemistry and Clinical Molecular Biology from the Italian Ministry of University and Research received on 06/15/2023)

Staff physician

Amyloidosis Research and Treatment Center, Laboratory of Biochemistry, Biotechnology and Advanced Diagnostics, IRCCS Foundation Policlinico San Matteo, Pavia, Italy

Clinical and diagnostic activities

Clinical activities:

Staff physician at the Amyloidosis Research and Treatment Center (since 2018).

Clinical activities in the outpatient clinic (management of patients with AL, ATTRwt, ATTRv and other hereditary amyloidoses).

Participation in clinical trials in the frame of AL, ATTRwt and ATTRv amyloidosis.

Molecular diagnostics:

Responsible for the Molecular Diagnostic Laboratory of the Italian Referral Center for Systemic Amyloidoses, IRCCS Foundation Policlinico San Matteo, Pavia, Italy (since 2018).

Main activities:

Coordinating and supervising molecular diagnostics activities for hereditary amyloidoses and systemic autoinflammatory diseases.

Member of the Genetics EQA Working Group of the International Society of Amyloidosis.

Education

11/2010 – 10/2013 PhD in Biomolecular sciences and biotechnologies, Institute for Advanced Studies of Pavia (IUSS), Italy (thesis title: "Generation of a conditional transgenic mouse model of immunoglobulin light chain (AL) amyloidosis"; date defence: 19/12/2013; PhD advisor Prof. Giampaolo Merlini)

10/2005 – 9/2010 Specialization in Internal Medicine, Faculty of Medicine, University of Pavia, Italy (thesis title, translated: "Liver involvement in AL

- amyloidosis: clinical and prognostic aspects in 225 patients”; date of defense: 25/10/2010, vote 50/50)
- 11/2005 License of professional medical practice, Faculty of Medicine, University of Pavia, Italy (score 270/270)
- 10/2000 – 9/2005 Medical degree *summa cum laude*, Faculty of Medicine, University of Pavia, Italy (thesis title, translated: “Clinical and molecular characterization of a new form of hereditary amyloidosis caused by apolipoprotein A-I”; date of defense 22/9/2005; M.D. advisor Prof. Giampaolo Merlini)

Professional experience

- Since 04/2022 Department of Molecular Medicine, University of Pavia, Italy
Associate Professor in Clinical Chemistry
Amyloidosis Research and Treatment Center, Laboratory of Biochemistry, Biotechnology and Advanced Diagnostics, IRCCS Foundation Policlinico San Matteo, Pavia, Italy
Staff physician (since 03/2018)
- 01/2017-03/2022 Department of Molecular Medicine, University of Pavia, Italy
Assistant Professor in Clinical Chemistry (since 01/2017)
Amyloidosis Research and Treatment Center, Laboratory of Biochemistry, Biotechnology and Advanced Diagnostics, IRCCS Foundation Policlinico San Matteo, Pavia, Italy
- 10/2007-12/2016 Department of Pathology, University Hospital Zürich, Zürich, Switzerland – Laboratory of Prof. Adriano Aguzzi
Visiting scientist and postdoc
- 03 – 09/2007 Genetics and Cell Biology Unit, Università Vita Salute San Raffaele Scientific Institute, Milan, Italy – Laboratory of Prof. Roberto Sitia
Visiting scientist
- 10/2005 – 9/2010 Internal Medicine Clinic, Italian Referral Center for Systemic Amyloidoses, Laboratories of Biotechnology, University Hospital San Matteo, Department of Internal Medicine and Department of Biochemistry, University of Pavia, Italy
Resident in Internal Medicine

Additional education and training

- 01/2020 Recognition as European Specialist in Laboratory Medicine, (EuSpLM) from the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Profession Committee ed (listed in the European Registry of Specialists in Laboratory Medicine, Nr. 4747)
- 03/2013 Course for directing animal experiments (LTK Module 2), LTK, University of Zürich, Switzerland (FELASA category C education)
- 08/2008 Introductory course in laboratory animal science (LTK Module 1), LTK, University of Zürich, Switzerland (FELASA category B education)

10/2001-12/2005 Course in Biomedical Sciences, Institute for Advanced Studies of Pavia (IUSS), Italy

Languages

Italian: mother tongue

English: fluent

French: fluent

German: intermediate

Awards and research grants

- 2021 Research grant of Oncopeptides, Inc., for the project "Investigating the therapeutic effect of Melflufen in preclinical models of AL amyloidosis" (role: PI)
- 2020 Research grant of the Global Bridges at Mayo Clinic and Pfizer Global Medical Grants, call "Raising Awareness and Promoting Timely Diagnosis of TTR Amyloidosis", for the project "The Italian transthyretin amyloidosis web network" (role: Co-PI)
- 2019 Research grant of the Italian Ministry of Health, Call for young investigators, for the project "Towards effective, patient-tailored anti-plasma cell therapies in AL amyloidosis: Predicting drug response and overcoming drug resistance" (role: PI)
- 2018 Research grant of the CARIPO Foundation for the project "Harnessing the plasma cell secretory capacity against systemic light chain amyloidosis" (role: Partner)
- 2018 Prize for best poster presentation at the 50th National Congress of the Italian Society of Clinical Chemistry and Clinical Molecular Biology (SIBioC). October 16th-18th, 2018. Naples, Italy
- 2018 Research grant of the Cancer Research UK for the project "Early detection and intervention: Understanding the mechanisms of transformation and hidden resistance of incurable haematological malignancies" (role: collaborator)
- 2018 Research grant of the Amyloidosis Foundation for the project "Inhibiting deubiquitinases to treat AL amyloidosis" (role: PI)
- 2018 International Society of Amyloidosis 2018 Presidential Travel Support to attend the XVth International Symposium on Amyloidosis, Kumamoto, Japan
- 2014 Junior Researcher Travel Award from the Amyloidosis Foundation to attend the XIIIth International Symposium on Amyloidosis, Indianapolis, USA
- 2013 Research grant of the Stiftung für Forschung an der Medizinischen Fakultät der UZH (postdoc) for the project "Modelling immunoglobulin light chain (AL) amyloidosis in mice" (Role: PI)

2012	Research award of the Foundation IRCCS San Matteo Hospital of Pavia for the project “Modelling immunoglobulin light chain (AL) amyloidosis in mice”
2011	Research grant of the Theodor und Ida Herzog-Egli Stiftung for the project “Modelling immunoglobulin light chain (AL) amyloidosis in mice” (role: PI)
2010	Annual fellowship of the Research Center – Collegio Ghislieri of Pavia to pursue basic research on systemic AL amyloidosis and other protein misfolding and deposition diseases
2008	Annual fellowship of the International Exchange Programs between the Collegio Ghislieri of Pavia and the University of Zürich, Switzerland
2007	Annual fellowship of the International Exchange Programs between the Collegio Ghislieri of Pavia and the University of Zürich, Switzerland
2006	Prize for best poster presentation at the 38 th National Congress of the Italian Society of Clinical Chemistry and Clinical Molecular Biology (SIBioC). September 19 th -22 nd , 2006. Turin, Italy
2005	Annual fellowship of the Research Center – Collegio Ghislieri of Pavia to pursue clinical and basic research on AL amyloidosis
2005	Summer fellowship of the International Exchange Programs between the Collegio Ghislieri of Pavia and the Saint John’s College of Cambridge – University of Cambridge, UK
2002	Summer fellowship of the International Exchange Programs between the Collegio Ghislieri of Pavia and the Johannes Gutenberg Universität of Mainz, Germany
2001	Summer fellowship of the International Federation of Medical Students Associations (IFMSA) to attend the Surgery Department of the University Hospital of Poznan, Poland
2001 – 2005	Selected by the Institute for Advanced Studies of Pavia (IUSS) for Undergraduate Internal Course in Biomedical Sciences
2000 – 2007	Alumnus of Collegio Ghislieri of Pavia, hall of residence situated in Pavia and recognized by the Italian Ministry of Education and Research as a highly qualified cultural institute

Teaching activities

- Courses and modules:
 - Specialization school in Clinical Pathology and Clinical Chemistry (2017/18 – present)
 - Specialization school in Allergology and Clinical Immunology (1 CFU, 2022/23 – present)
 - Specialization school in Othorinolaringoiatry (1 CFU, 2022/23 – present)
 - Module “Clinical Chemistry”, part of the course “Laboratory Medicine” [506708], Medical School (Harvey course) [04401]
-

- (1 CFU, 2017/18 – present)
- Module “Metodologia di Biochimica e Biologia Molecolare Clinica”, part of the course “Genoma: Analisi e applicazioni diagnostiche” [503959], Master degree in Medical and Pharmaceutical Biotechnologies [37400] (1 CFU, 2017/18 – 2021/22)
- Course “Il laboratorio d’urgenza” [504201], Bachelor for Technicians of Biomedical Laboratory [04413] (2 CFU, 2017/18 – 2022/23)
- Module di “Metodologie diagnostiche molecolari”, part of the course “Biochimica clinica e tossicologia” [503658], Bachelor for Technicians of Biomedical Laboratory (2 CFU, 2018/19 – present)
- Course “Metodologia diagnostica molecolare” [502027], Bachelor in Biotechnologies [35400] (3 CFU, 2020/21 – present)
- Module “Biomarkers and Biochemical Diagnosis”, part of the course “Chemical and Biochemica Foundations” [509944], Master degree in Medical and Pharmaceutical Biotechnologies [37401] (2 CFU, 2022/23 – present)
- Course “Il ruolo della medicina di laboratorio nella clinica” [510289], Bachelor for Technicians of Biomedical Laboratory [04413] (1 CFU, 2022/23)
- Course “Metodologia della ricerca biomedica” [510248], Bachelor for Technicians of Biomedical Laboratory [04413] (1 CFU, 2022/23)
- Member of the PhD program in in Translational and Precision Medicine, Department of Molecular Medicine, University of Pavia (38th cycle, 2022/23 – present)
- Supervisor of numerous students for the preparation of their bachelor, master and doctoral thesis
- Additional teaching activities:
 - Centro Europeo per la Formazione, l’Aggiornamento e la Ricerca in Scienze Sanitarie e in Biotecnologie (CEFAR): Invited lecture: Free light chains and AL amyloidosis. XXIV Edition Course of CEFAR: Proteins: from the laboratory to the clinic. Naples, Italy (06/05/2016)
 - Co-organizer and co-supervisor of the series of seminars entitled "Interdisciplinary Technical Journal Club: special series on Laboratory Animal Science" at the University Hospital of Zurich, recognized by the Cantonal Office of Zurich as a continuing training course for personnel involved in experiments animals
 - Speaker at conferences, seminars and invited readings at national and international level

Research activities

Prof. Nuvolone's research activity initially took place at the Biochemistry, Biotechnology and Advanced Diagnostics Laboratories and the Center for the Study and Treatment of Systemic Amyloidosis, Fondazione IRCCS Policlinico San Matteo and University of Pavia, under the direction of Prof. Giampaolo Merlini, and subsequently at the Swiss Reference

Center for prion diseases, University Hospital of Zurich (CH), under the direction of Prof. Adriano Aguzzi, and focused on protein misfolding diseases, with particular reference to systemic amyloidoses and prion diseases.

In 2017, after a 9-year period in Zurich, Prof. Nuvolone returned to Pavia first as a Researcher (RTDa and RTDb) and subsequently as an Associate Professor in Clinical Biochemistry and Clinical Molecular Biology, working at the Biochemistry Biotechnology Laboratories and Advanced Diagnostics and the Center for the Study and Treatment of Systemic Amyloidosis, Fondazione IRCCS Policlinico San Matteo and University of Pavia (Director: Prof. Giampaolo Merlini and subsequently Prof. Giovanni Palladini). The return to Italy was mainly motivated by the desire to transfer knowledge from basic research to clinical practice to improve patient outcomes, considering Clinical Biochemistry an ideal discipline for this objective. In fact, the driving force of Prof. Nuvolone's research activity is that of translational laboratory research aimed at addressing the unmet medical needs generated by the recent progress achieved in the diagnosis and treatment of monoclonal gammopathies and protein misfolding diseases – including the need for highly sensitive analytical methods for the detection and characterization of monoclonal components and the advantage of performing molecular profiling of clonal disease for personalized diagnostic and therapeutic approaches – for which Laboratory Medicine plays a central role.

Over the years, Prof. Nuvolone has initiated new lines of research aimed at the development of new advanced diagnostic methods and the use of genomic, transcriptomic and proteomic approaches for the study of molecular mechanisms of disease and for the development of new diagnostic and therapeutic approaches, acquiring independent funding from competitive calls, initiating new scientific collaborations at local, national and international level, and building and directing a dedicated group for laboratory research.

Memberships in scientific societies

Società Italiana per l'Amiloidosi (SIA)

International Society of Amyloidosis (ISA)

Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica (SIBioC)

Editorial activity

Member of the editorial board of Amyloid, Front Neurol, Front Neurosci, Front Psych, Matters

Reviewer activity

Member of the Technical Health Committee (Comitato Tecnico Sanitario) of the Italian Ministry of Health (Nov. 2018 – Dec. 2021)

Member of the evaluation committee for grants of the Italian Ministry of Health (progetti Estero, progetti Rete, progetti Cofinanziati)

Member of the evaluation committee for grants of the Italian Medicines Agency (AIFA)

Ad hoc reviewer for grants of the National Science Center, Poland

Ad hoc reviewer for JAMA Oncology, JCI Insight, Clin Transl Med, Kidney Int, Kidney Int Rep, J Nephrol, BMC Nephrol, Sci Rep, Amyloid, Swiss Med Wkly, BMJ Open, Am J Hematol, Haematologica, Br J Hematol, Leuk Lymphoma, Hematol Oncol, Hemato, Front Immunol, Front Oncol, Tumori Journal, Clin Chem Lab Med, Clin Ther, Mol Neurobiol, Front Neurosci, Neurol Therapy, Brain Res, ACS Chem Neurosci, J Gen Virol, Exp Opin Biol Ther, Pract Lab Med, Int Res J Med Med Sci, Int J Clin Pract, Clin Case Rep, Biochimica Clinica

Patents

Filing of industrial patent application entitled "Method for the identification of the entire sequence of the variable region of the heavy and light chains of immunoglobulins" with the Ministry of Economic Development (submission date: 07/21/2021, ownership share: 89%)

International patent (Patent Cooperation Treaty, PCT) entitled "Method for the identification of the whole sequence of the variable region of the heavy and light chains of immunoglobulins" at the World Intellectual Property Organization – International Bureau (International Publication Number: WO 2023/ 002402 A1; publication date: 01/26/2023, ownership share 89%)

Publications

Dr. Nuvolone has authored 83 publications (PubMed). Total citations: 2744; H index: 24 (Scopus).

Peer-reviewed publications:

1. Natali E, Horst A, Meier P, Greiff V, **Nuvolone M**, Babrak L, FinkK, Miho E. The dengue-specific immune response and antibody identification with machine learning. *NPJ Vaccines* (in press).
2. **Nuvolone M**, Merlini G. Mining the amyloid-plaque proteome to uncover disease mechanisms in renal amyloidoses. *Kidney Int* (in press).
3. Broggin L, Barzago MM, Speranzini V, Schulte T, Sonzini F, Giono M, Romeo M, Milani P, Caminito S, Mazzini G, Rognoni P, Merlini G, Pappone C, Anastasia L, **Nuvolone M**, Palladini G, Diomede L, Ricagno S. Nanobodies counteract the toxicity of an amyloidogenic light chain by stabilizing a partially open dimeric conformation. *J Mol Biol* 2023;435:168320.
4. Puri S, Schulte T, Chaves-Sanjuan A, Mazzini G, Caminito S, Pappone C, Anastasia L, Milani P, Merlini G, Bolognesi M, **Nuvolone M**, Palladini G, Ricagno S. The Cryo-EM structure of renal amyloid fibril suggests structurally homogeneous multiorgan aggregation in AL amyloidosis. *J Mol Biol* 2023;435:168215.
5. Nevone A, Lattarulo F, Russo M, Panno G, Milani P, Basset M, Avanzini MA, Merlini G, Palladini G, **Nuvolone M**. A strategy for the selection of RT-qPCR reference genes based on publicly available transcriptomic data sets. *Biomedicines* 2023;11:1079.
6. **Nuvolone M**, Girelli M, Merlini G. Oral therapy for the treatment of transthyretin-related amyloid cardiomyopathy. *Int J Mol Sci* 2022;23:16145.
7. Schulte T, Chaves-Sanjuan A, Mazzini G, Speranzini V, Lavatelli F, Ferri F, Palizzotto C, Mazza M, Milani P, **Nuvolone M**, Vogt AC, Vogel M, Palladini G, Merlini G, Bolognesi M, Ferro S, Zini E, Ricagno S. Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter. *Nat Commun* 2022;13(1):7041.
8. **Nuvolone M**, Nevone A, Merlini G. Targeting amyloid fibrils by passive immunotherapy in systemic amyloidosis. *BioDrugs* 2022 Sep;36(5):591-608.
9. Cascino P, Nevone A, Piscitelli M, Scopelliti C, Girelli M, Mazzini G, Caminito S, Russo G, Milani P, Basset M, Foli A, Fazio F, Casarini S, Massa M, Bozzola M, Ripepi J, Sesta MA, Acquafredda G, De Cicco M, Moretta A, Rognoni P, Milan E, Ricagno S, Lavatelli F, Petrucci MT, Miho E, Klersy C, Merlini G, Palladini G, **Nuvolone M**. Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies. *Am J Hematol* 2022;97:E389-E392.
10. Basset M, Milani P, Foli A, **Nuvolone M**, Benvenuti P, Nanci M, Fabris F, Bellofiore C, Merlini G, Palladini G. Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival. *Blood* 2022;140:1964-1971.
11. Liu Y, Senatore A, Sorce S, **Nuvolone M**, Guo J, Gümüş ZH, Aguzzi A. Brain aging is faithfully modelled in organotypic brain slices and accelerated by prions. *Commun Biol*. 2022 Jun 8;5(1):557.
12. Nevone A, Girelli M, Mangiacavalli S, Paiva B, Milani P, Cascino P, Piscitelli M, Speranzini V, Cartia CS, Benvenuti P, Goicoechea I, Fazio F, Basset M, Foli A, Nanci M, Mazzini G, Caminito S, Sesta MA, Casarini S, Rognoni P, Lavatelli F, Petrucci MT, Olimpieri PP, Ricagno S, Arcaini L, Merlini G, Palladini G, **Nuvolone M**. An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis. *Leukemia* 2022;36:2076-2085.

13. Lakkaraju AKK, Sorce S, Senatore A, **Nuvolone M**, Guo J, Schwarz P, Moos R, Pelczar P, Aguzzi A. Glial activation in prion diseases is selectively triggered by neuronal PrP^{Sc}. *Brain Pathol.* 2022;32:e13056.
14. Matamoros-Angles A, Hervera A, Soriano J, Martí E, Carulla P, Llorens F, **Nuvolone M**, Aguzzi A, Ferrer I, Gruart A, Delgado-García JM, Del Río JA. Analysis of co-isogenic prion protein deficient mice reveals behavioral deficits, learning impairment, and enhanced hippocampal excitability. *BMC Biol.* 2022;20:17.
15. Basset M, Milani P, Ferretti VV, **Nuvolone M**, Foli A, Benigna F, Nanci M, Bozzola M, Ripepi J, Sesta M, Russo F, Bosoni T, Klersy C, Albertini R, Merlini G, Palladini G. Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients. *Clin Chem Lab Med* 2022;60:386-393.
16. Valsecchi C, Croce S, Maltese A, Montagna L, Lenta E, Nevone A, Girelli M, Milani P, Bosoni T, Massa M, Abbà C, Campanelli R, Ripepi J, De Silvestri A, Carolei A, Palladini G, Zecca M, **Nuvolone M**, Avanzini MA. Bone marrow microenvironment in light-chain amyloidosis: in vitro expansion and characterization of mesenchymal stromal cells. *Biomedicines* 2021;9:1523.
17. Mazzini G, Ricagno S, Caminito S, Rognoni P, Milani P, **Nuvolone M**, Basset M, Foli A, Russo R, Merlini G, Palladini G, Lavatelli F. Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation. *FEBS J (In press)*
18. Palladini G, Celant S, Milani P, Summa V, Affronti G, Olimpieri PP, Petraglia S, Foli A, **Nuvolone M**, Merlini G, Russo P. A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis. *Leuk Lymphoma (In press)*
19. Alameda D, Goicoechea I, Vicari M, Arriazu E, Nevone A, Rodríguez S, Lasa M, Puig N, Cedena MT, Alignani D, Garate S, Lara-Astiaso D, Vilas-Zornoza A, Sarvide S, Ocio EM, Lecumberri R, Garcia de Coca A, Labrador J, Gonzalez ME, Palomera L, Gironella M, Cabañas V, Casanova M, Oriol A, Krsnik I, Pérez-Montaña A, de la Rubia J, de la Puerta JE, de Arriba F, Fazio VM, Martinez-Lopez J, Lahuerta JJ, Mateos MV, Odero MD, Prosper F, Weiner A, Amit I, **Nuvolone M**, San-Miguel JFF, Paiva B. Tumor cells in light-chain amyloidosis and myeloma show different transcriptional rewiring of normal plasma cell development. *Blood (In press)*
20. Lidón L, Llaó-Hierro L, **Nuvolone M**, Aguzzi A, Ávila J, Ferrer I, Del Río JA, Gavín R. Tau Exon 10 Inclusion by PrPC through Downregulating GSK3 β Activity. *Int J Mol Sci* 2021;22:5370.
21. Meisl G, Kurt T, Condado-Morales I, Bett C, Sorce S, **Nuvolone M**, Michaels TCT, Heinzer D, Avar M, Cohen SIA, Hornemann S, Aguzzi A, Dobson CM, Sigurdson CJ, Knowles TPJ. Scaling analysis reveals the mechanism and rates of prion replication in vivo. *Nat Struct Mol Biol* 2021;28:365-372.
22. Palladini G, Paiva B, Wechalekar A, Massa M, Milani P, Lasa M, Ravichandran S, Krsnik I, Basset M, Burgos L, **Nuvolone M**, Lecumberri R, Foli A, Puig N, Sesta MA, Bozzola M, Cascino P, Nevone A, Ripepi J, Berti P, Casarini S, Annibaldi O, Orfao A, San-Miguel J, Merlini G. Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. *Blood Cancer J* 2021;11:34.
23. **Nuvolone M**, Basset M, Palladini G. A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis. *Exp Opin Drug Saf* 2021;20:411-426.
24. Fucci C, Resnati M, Riva E, Perini T, Ruggieri E, Orfanelli U, Paradiso F, Cremasco F, Raimondi A, Pasqualetto E, **Nuvolone M**, Rampoldi L, Cenci S, Milan E. The Interaction of the Tumor Suppressor FAM46C with p62 and FNDC3 Proteins Integrates Protein and Secretory Homeostasis. *Cell Rep* 2020; 32:108162.
25. Lavatelli F, Mazzini G, Ricagno S, Iavarone F, Rognoni P, Milani P, **Nuvolone M**, Swuec P, Caminito S, Tasaki M, Chaves-Sanjuan A, Urbani A, Merlini G, Palladini G. Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis. *J Biol Chem* 2020; 295:16572-16584.
26. Basset M, Milani P, **Nuvolone M**, Benigna F, Rodigari L, Foli A, Merlini G, Palladini G. Sequential, response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis. *Blood Adv* 2020;4:4175-4179.
27. Milani P, Basset M, **Nuvolone M**, Benigna F, Rodigari L, Lavatelli F, Foli A, Merlini G, Palladini G. Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy. *Blood Cancer J* 2020;10:90.
28. **Nuvolone M** and Merlini G. Redirecting proteotoxicity. *Leukemia* 2020;4:3109-3110.
29. Nevone A, Merlini G, **Nuvolone M**. Treating protein misfolding diseases: therapeutic successes against systemic amyloidosis. *Front Pharmacol* 2020;11:1024.
30. Basset M, **Nuvolone M**, Palladini G, Merlini G. Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside. *Expert Rev Hematol* 2020;13:1003-1015.
31. Sorce S*, **Nuvolone M***, Russo G, Chincisan A, Heinzer D, Avar M, Pfammatter M, Schwarz P, Delic M, Müller M, Hornemann S, Sanoudou D, Scheckel C, Aguzzi A. Genome-wide transcriptomics identifies an early preclinical signature of prion infection. *PLoS Pathog* 2020;16:e1008653.

32. Milani P, Sharpley F, Schönland SO, Basset M, Mahmood S, **Nuvolone M**, Kimmich C, Foli A, Sachchithanantham S, Merlini G, Wechalekar A, Palladini G, Hegenbart U. Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients. *Amyloid* 2020;27:231-236.
33. Milani P, Fazio F, Basset M, Berno T, Larocca A, Foli A, Riva M, Benigna F, Oliva S, **Nuvolone M**, Rodigari L, Petrucci MT, Merlini G, Palladini G. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate. *Am J Hematol* 2020;95:900-905.
34. Milani P, Basset M, Curci P, Foli A, Rizzi R, **Nuvolone M**, Guido R, Gesualdo L, Specchia G, Merlini G, Palladini G. Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function. *Blood Adv* 2020;4:1321-1324
35. Caccialanza R, Cereda E, Klersy C, Milani P, Cappello S, Martinelli V, Turri A, Basset M, Borioli V, **Nuvolone M**, Caraccia M, Lavatelli F, Masi S, Lobascio F, Foli A, Merlini G, Palladini G. Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis. *Amyloid* 2020;27:168-173.
36. Basset M, DeFrancesco I, Milani P, **Nuvolone M**, Rattotti S, Foli A, Mangiacavalli S, Varettoni M, Benvenuti P, Cartia CS, Paulli M, Merlini G, Arcaini L, Palladini G. Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis. *Blood* 2020;135:293-296
37. Tasaki M, Milani P, Foli A, Verga L, Obici L, Basset M, Bozzola M, Ferraro G, **Nuvolone M**, Morbini P, Capello G, Ueda M, Obayashi K, Paulli M, Ando Y, Merlini, Palladini G, Lavatelli F. Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients. *Blood* 2019;134:320-323.
38. **Nuvolone M**, Merlini G. New insights into a multifaceted disease. *Mayo Clin Proc.* 2019 Mar;94(3):388-390.
39. Ami D, Mereghetti P, Foli A, Tasaki M, Milani P, **Nuvolone M**, Palladini G, Merlini G, Lavatelli F, Natalello A. ATR-FTIR Spectroscopy Supported by Multivariate Analysis for the Characterization of Adipose Tissue Aspirates from Patients Affected by Systemic Amyloidosis. *Anal Chem.* 2019;91:2894-2900
40. **Nuvolone M**, Merlini G. Improved outcomes for kidney transplantation in AL amyloidosis: impact on practice. *Kidney Int.* 2019;95:258-260
41. Keller A, **Nuvolone M**, Abakumova I, Chincisan A, Reimann R, AvarM, Heinzer D, Hornemann S, Wagner J, Kirschenbaum D, Voigt FF, Zhu C, Regli L, Helmchend F, Aguzzi A. Prion pathogenesis is unaltered in a mouse strain with a permeable blood-brain barrier. *PLoS Pathogens.* 2018;14:e1007424
42. Liu Y, Sorce S, **Nuvolone M**, Domange J, Aguzzi A. Lymphocyte activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression. *Sci Rep.* 2018;8:14600
43. **Nuvolone M**, Milani P, Palladini G, Merlini G. Management of the elderly patient with AL amyloidosis. *Eur J Int Med.* 2018 2018;58:48-56
44. **Nuvolone M**, Merlini G. Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis. *Expert Opin Ther Targets.* 2017;21:1095-110.
45. **Nuvolone M**, Paolucci M, Sorce S, Kana V, Moos R, Matozaki T, Aguzzi A. Prion pathogenesis is unaltered in the absence of SIRP α -mediated "don't-eat-me" signaling. *PLoS One.* 2017;12(5):e0177876.
46. Milani P, Basset M, Russo F, Foli A, Lavatelli F, **Nuvolone M**, Ferraro G, Palladini G, Merlini G. Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome. *Amyloid.* 2017;24(sup1):64-65.
47. Basset M, Milani P, Russo F, Lavatelli F, **Nuvolone M**, Foli A, Perlini S, Palladini G, Merlini G. Patterns of relapse after upfront bortezomib therapy in AL amyloidosis. *Amyloid.* 2017;24(sup1):60-61.
48. Palladini G, Milani P, Basset M, Russo F, Lavatelli F, **Nuvolone M**, Ferraro G, Bozzola M, Foli A, Merlini G. Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis. *Amyloid.* 2017;24(sup1):68-69.
49. Russo F, Valentini V, Basset M, Bosoni T, Milani P, Ferraro G, Pirolini L, Foli A, Lavatelli F, Belvisi F, Consogno G, **Nuvolone M**, Li Bergolis F, Bozzola M, Albertini R, Palladini G, Merlini G. Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis. *Amyloid.* 2017 Mar;24(sup1):66-67.
50. Palladini G, Milani P, Basset M, Russo F, Lavatelli F, **Nuvolone M**, Ferraro G, Bozzola M, Foli A, Perlini S, Merlini G. Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response. *Amyloid.* 2017;24(sup1):54-55.
51. Palladini G, Riva E, Basset M, Russo F, Milani P, Pasquinucci E, Foli A, Lavatelli F, **Nuvolone M**, Casarini S, Obici L, Merlini G. Prognostication of survival and progression to dialysis in AA amyloidosis. *Amyloid.* 2017;24(sup1):136-137.

52. **Nuvolone M**, Sorce S, Paolucci M, Aguzzi A. Extended characterization of the novel co-isogenic C57BL/6J Prnp^{-/-} mouse line. *Amyloid*. 2017;24(sup1):36-37.
53. **Nuvolone M**, Sorce S, Pelczar P, Rushing E, Lavatelli F, Rognoni P, Valentini V, Palladini G, Merlini G, Aguzzi A. Regulated expression of amyloidogenic immunoglobulin light chains in mice. *Amyloid*. 2017;24(sup1):52-53.
54. Palladini G, Jaccard A, Milani P, Lavergne D, Foli A, Bender S, Lavatelli F, Bosoni T, Valentini V, Pirolini L, Ferraro G, Basset M, Russo F, **Nuvolone M**, Albertini R, Cogne M, Merlini G. Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays. *Clin Chem Lab Med*. 2017 [Epub ahead of print]
55. **Nuvolone M**, Schmid N, Miele G, Sorce S, Moos R, Schori C, Beerli RR, Bauer M, Saudan P, Dietmeier K, Lachmann I, Linnebank M, Martin R, Kallweit U, Kana V, Rushing EJ, Budka H, Aguzzi A. Cystatin F is a biomarker of prion pathogenesis in mice. *PLoS One*. 2017; 12:e0171923.
56. **Nuvolone M**, Merlini G. Systemic amyloidosis: novel therapies and role of biomarkers. *Nephrol Dial Transplant*. 2017;32:770-780.
57. Küffer A*, Lakkaraju AKK*, Mogha A, Petersen SC, Airich K, Doucerain C, Marpakwar R, Bakirci P, Senatore A, Monnard A, Schiavi C, **Nuvolone M**, Grosshans B, Hornemann S, Bassilana F, Monk KR, Aguzzi A. The prion protein is an agonistic ligand of the G protein-coupled receptor Gpr126/Adgrg6. *Nature*. 2016;536:464-8.
58. Obici L, **Nuvolone M**, Merlini G. Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney. *Kidney Int*. 2016;90:479-81.
59. Requena JR, Kristensson K, Korth C, Zurzolo C, Simmons M, Aguilar-Calvo P, Aguzzi A, Andreoletti O, Benestad SL, Böhm R, Brown K, Calgua B, Del Río JA, Espinosa JC, Girones R, Godsave S, Hoelzle LE, Knittler MR, Kuhn F, Legname G, Laeven P, Mabbott N, Mitrova E, Müller-Schiffmann A, **Nuvolone M**, Peters PJ, Raeber A, Roth K, Schmitz M, Schroeder B, Sonati T, Stitz L, Taraboulos A, Torres JM, Yan ZX, Zerr I. The Priority position paper: Protecting Europe's food chain from prions. *Prion*. 2016;10:165-81.
60. Zhu C*, Herrmann US*, Falsig J, Abakumova I, **Nuvolone M**, Schwarz P, Frauenknecht K, Rushing EJ, Aguzzi A. A neuroprotective role for microglia in prion diseases. *J Exp Med*. 2016;213:1047-59.
61. **Nuvolone M***, Hermann M*, Sorce S, Russo G, Tiberi C, Schwarz P, Minikel E, Sanoudou D, Pelczar P, Aguzzi A. Strictly co-isogenic C57BL/6J-Prnp^{-/-} mice: a rigorous resource for prion science. *J Exp Med*. 2016;213:313-27.
62. **Nuvolone M**, Aguzzi A. Altered monoaminergic systems and depressive-like behavior in congenic prion protein knock-out mice. *J Biol Chem* 2015;290:26350.
63. Herrmann US, Schütz AK, Shirani H, Huang D, Saban D, **Nuvolone M**, Li B, Ballmer B, Åslund AK, Mason JJ, Rushing E, Budka H, Nyström S, Hammarström P, Böckmann A, Caflisch A, Meier BH, Nilsson KP, Hornemann S, Aguzzi A. Structure-based drug design identifies polythiophenes as antiprion compounds. *Sci Transl Med* 2015; 7:299ra123.
64. **Nuvolone M**, Sorce S, Schwarz P, Aguzzi A. Prion pathogenesis in the absence of NLRP3/ASC inflammasomes. *PLoS One* 2015; e0117208.
65. Sorce S, **Nuvolone M**, Keller A, Falsig J, Varol A, Schwarz P, Bieri M, Budka H, Aguzzi A. The role of the NADPH oxidase NOX2 in prion pathogenesis. *PLoS Pathogenes* 2014;10: e1004531.
66. Palladini G, Milani P, Foli A, Vidus Rosin M, Basset M, Lavatelli F, **Nuvolone M**, Obici L, Perlini S, Merlini G. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. *Leukemia* 2014;28: 2311-6.
67. Palladini G, Milani P, Foli A, Obici L, Lavatelli F, **Nuvolone M**, Caccialanza R, Perlini S, Merlini G. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. *Haematologica* 2014;99:743-50.
68. Aguzzi A, **Nuvolone M**, Zhu C. The Immunobiology of prions. *Nat Rev Immunol* 2013;13:888-902.
69. **Nuvolone M***, Kana V*, Hutter G*, Sakata D, Mortin-Toth SM, Russo G, Danska JS, Aguzzi A. Sirpa polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells. *J Exp Med* 2013;210:2539-52.
70. Sponarova J, **Nuvolone M**, Whicher C, Nathalie Frei, Veronika Kana, Petra Schwarz, Westermarck GT, Aguzzi A. Natural macrophage-mediated clearance of Amyloid A is efficient in the absence of immunoglobulins or complement factors C3 and C4. *Am J Pathol* 2013;182:1297-307.
71. Palladini G, Russo P, Milani P, Foli A, Lavatelli F, **Nuvolone M**, Perlini S, Merlini G. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. *Haematologica* 2013;98:433-6.
72. Larson M, Sherman MA, Amar F, **Nuvolone M**, Schneider JA, Bennet DA, Aguzzi A, Lesné SE. The complex PrPC-Fyn couples human A β oligomers with pathological tau changes in Alzheimer's disease. *J Neurosci* 2012;47:16857-71.

73. Palladini G, Russo P, Foli A, Milani P, Lavatelli F, Obici L, **Nuvolone M**, Brugnattelli S, Invernizzi R, Merlini G. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. *Ann Hematol* 2012;91:89-92.
74. Russo P, Palladini G, Foli A, Zenone Bragotti L, Milani P, **Nuvolone M**, Obici L, Perfetti V, Brugnattelli S, Invernizzi R, Merlini G. Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients. *Amyloid* 2011; Suppl 1:87-8.
75. Peters R*, Wolf MJ*, van den Broek M, **Nuvolone M**, Dannenmann S, Stieger B, Rapold R, Rubin A, Bertino JR, Aguzzi A, Heikenwalder M, Knuth AK. Efficient generation of multipotent mesenchymal stem cells from umbilical cord blood in stroma-free liquid culture. *PLoS One* 2010;5:e15689.
76. Calella AM*, Farinelli M*, **Nuvolone M***, Mirante O, Moos R, Falsig J, Mansuy IM, Aguzzi A. Prion protein and A β -related synaptic toxicity impairment. *EMBO Mol Med* 2010;2:306-14.
77. Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, **Nuvolone M**, Obici L, Casarini S, Donadei S, Albertini R, Righetti G, Marini M, Graziani MS, Melzi D'Eril GV, Moratti R, Merlini G. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. *Clin Chem* 2009;55:499-504.
78. Palladini G, Russo P, Lavatelli F, **Nuvolone M**, Albertini R, Bosoni T, Perfetti V, Obici L, Perlini S, Moratti R, Merlini G. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. *Ann Hematol* 2009;88:347-50.
79. **Nuvolone M**, Aguzzi A, Heikenwalder M. Cells and prions: a license to replicate. *FEBS Lett* 2009;583:2674-84
80. Palladini G, Russo P, **Nuvolone M**, Lavatelli F, Perfetti V, Obici L, Merlini G. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. *Blood* 2007;110:787-8.
81. Bellotti V, **Nuvolone M**, Giorgetti S, Obici L, Palladini G, Russo P, Lavatelli F, Perfetti V, Merlini G. The workings of the amyloid diseases. *Ann Med* 2007;39:200-7.
82. Invernizzi R, Palladini G, Benatti C, Travaglio E, **Nuvolone M**, Merlini G. Bone marrow amyloidosis. *Haematologica* 2006; 91:(EIM)01.

* equally contributing authors

Book chapters:

1. **Nuvolone M**, Palladini G, Merlini G. Amyloidosis at a molecular level: General overview and focus on AL amyloidosis. In "Systemic Amyloid and Related Disorders: Surgical Pathology and Clinical Correlations". Edited by M.M. Picken, A. Dogan and G. Herrera. *New York, Springer*. 2012.
2. **Nuvolone M**, Palladini G, Merlini G. Amyloidosis at a molecular level: General overview and focus on AL amyloidosis. In "Amyloid and Related Disorders: Surgical Pathology and Clinical Correlations". 2nd edition. Edited by M.M. Picken, A. Dogan and G. Herrera. *New York, Springer*. 2015.

Publications in national journals:

1. Nevone A, Sesta MA, Mazzini G, Caminito S, Lattarulo F, Russo M, Corpina C, Novello E, Nanci M, Basset M, Milani P, Massa M, Merlini G, Palladini G, **Nuvolone M**. Un caso di amiloidosi sistemica AL apparentemente senza clone correlato: ruolo della diagnostica avanzata di laboratorio. *Biochimica Clinica* 2023 *In press*
2. Nevone A, Mazzini G, Caminito S, Girelli M, Russo M, Lattarulo F, Sesta MA, Corpina C, Novello E, Nanci M, Basset M, Milani P, Merlini G, Palladini G, **Nuvolone M**. Iter diagnostico dei pazienti con sospetta amiloidosi cardiaca: il ruolo guida del laboratorio diagnostico. *Biochimica Clinica* 2023 *In press*
3. Basset M, **Nuvolone M**, Palladini G. Amiloidosi renali. *Biochimica Clinica* 2021; 45(3): s025-s036
4. Nevone A, Cascino P, Girelli M, Scopelliti C, Piscitelli M, Bozzola M, Sesta MA, Ripepi J, Milani P, Basset M, Palladini G, **Nuvolone M**. Analisi dei livelli trascrizionali di ciclina D1 nello studio delle discrasie plasmacellulari: revisione sistematica della letteratura. *Biochimica Clinica* 2021; 45(3): 230-241
5. Ripepi J, Basset M, Milani P, **Nuvolone M**, Foli A, Bozzola M, Bosoni T, Albertini R, Palladini G. Una complicata valutazione della risposta alla terapia in un paziente con malattia da deposito di catene leggere libere. *Biochimica Clinica* 2020; 44(4) e30-e33
6. Basset M, Bozzola M, Ripepi J, Milani P, **Nuvolone M**, Lavatelli F, Ferraro G, Bosoni T, Pirolini L, Albertini R, Palladini G. I marcatori di clonalità per la diagnosi e la valutazione della risposta alla terapia nell'amiloidosi da catene leggere: il ruolo del laboratorio. *Biochimica Clinica* 44(2) E09-E13.
7. Ripepi J, Basset M, Bozzola M, Milani P, **Nuvolone M**, Lavatelli F, Ferraro G, Bosoni T, Pirolini L, Albertini R, Palladini G. Un caso di gammopatia monoclonale di significato renale. *Biochimica Clinica* 44(2) E06-E08

8. Nevone A, Cascino P, Bozzola M, Palladini G, **Nuvolone M**. Identificazione di geni di normalizzazione per studi trascrizionali con PCR quantitativa: revisione della letteratura. *Biochimica Clinica* 43(4) 357-365
9. Sancesario G, Perrone MA, Pellegrini C, Ialongo C, Aita A, Kumar Dabla P, Fares Taie S, Favresse J, Velts-Lindh A, D'Argenio V, Ammirabile M, Spolaore F, Renzi C, **Nuvolone M**, Cariati F, Bellini C, Benati M, Salvagno GL, Plebani M, Bernardini S. La Medicina di Laboratorio: gli specialisti di domani. *Biochimica Clinica* 43(4) 424-434.
10. Basset M, Milani P, Russo F, **Nuvolone M**, Lavatelli F, Bosoni T, Pirolini L, Li Bergolis F, Foli A, Albertini R, Palladini G, Merlini G. Valutazione della risposta alla terapia in un paziente con amiloidosi AL e basse concentrazioni della catena leggera libera monoclonale. *Biochimica Clinica* 43(1) e4-e6
11. Milani P, Basset M, Russo F, **Nuvolone M**, Lavatelli F, Bosoni T, Pirolini L, Li Bergolis F, Foli A, Albertini R, Palladini G, Merlini G. La misura delle catene leggere libere indentifica la ricaduta di malattia e orienta per una rivalutazione della tipizzazione dell'amiloide in una paziente con amiloidosi AL. *Biochimica Clinica* 42(2) e15-e17.
12. Rauch PJ, Müllhaupt B, Biedermann L, Manz MG, Ruschitzka F, Flammer A, Segerer S, Mohebbi N, Jung HH, Moch H, Ikenberg K, Aguzzi A, **Nuvolone M**, Distler O, Rauch A, Fehr T, Gerber B. Systemische Amyloidosen. *Schweiz Med Forum* 2014;14:943–948.
13. **Nuvolone M**, Obici L, Merlini G. Transthyretin-associated familial amyloid polyneuropathy – current and emerging therapies *USA Neurology* 2012;8:24-32 (reproduction of review article previously published in *Eur Neurol Reviews*).
14. **Nuvolone M**, Obici L, Merlini G. Transthyretin-associated familial amyloid polyneuropathy – current and emerging therapies. *Eur Neurol Reviews* 2012;7:14-21.
15. Milani P, Palladini G, Russo P, Foli A, Zenone Bragotti L, **Nuvolone M**, Obici L, Perfetti V, Brugnattelli V, Invernizzi R, Merlini G. L'interessamento epatico come indicatore di malattia aggressiva nell'amiloidosi AL: ruolo delle catene leggere libere in 225 pazienti. *Bollettino della Società Medico Chirurgica di Pavia* 2010;123(2).
16. Johns AM, Merlini G, Sheldon J, Ichihara K, **Nuvolone M**. La transtiretina (prealbumina) nella infiammazione e malnutrizione. *Biochimica clinica* 2007; 31:97-104.
17. **Nuvolone M**, Palladini G, Russo P, Lavatelli F, Fogari R, Merlini G. Performance diagnostica del test quantitativo per le catene leggere libere circolanti nell'amiloidosi AL. *Bollettino della Società Medico Chirurgica di Pavia* 2006; 119 (1).
18. **Nuvolone M**, Palladini G, Russo P, Lavatelli F, Perlini S, Vezzoli M, Fogari R, Merlini G. Correlazione tra concentrazione sierica di cTnl e di NT-proBNP in pazienti con amiloidosi AL. *Bollettino della Società Medico Chirurgica di Pavia* 2006; 119 (1).

Oral presentations

1. Sequencing sick molecules: towards personalized medicine in monoclonal gammopathies. Amyloidosis Center, Boston University, December 1st (held online) (invited seminar).
2. Patient action plan for ATTR amyloidosis: The laboratory and extracardiac monitoring of patients with ATTR-CM. Hybrid Global Preceptorship – An Expert Center Experience, November 25th, 2023. Milan, Italy (invited lecture).
3. An introduction to cardiac amyloidosis. Hybrid Global Preceptorship – An Expert Center Experience, November 25th, 2023. Milan, Italy (invited lecture).
4. Novità nella diagnosi e nella terapia delle amiloidosi sistemiche. Il Nefrologo incontra gli altri specialisti – Il rene nelle discrasie plasmacellulari. November 17th, 2023. Catania, Italy (invited lecture).
5. ATTR amyloidosis: Pathogenesis and diagnosis. The National conference of Amyloidosis. November 11th, 2023. Bucharest, Romania (held online) (invited lecture).
6. Development of novel approaches for early diagnosis and disease management of AL amyloidosis. Accelerator – Editor, Final hub meeting. September 21st, 2023. Madrid, Spain.
7. Multicountry funding schemes challenges. WORKSHOP: Analysis of the bottlenecks and challenges in designing and conducting multicountry Investigator initiated clinical studies. Pillar 2B. ERA4Health Partnership. September 15th, 2023. Paris, France (invited lecture).
8. Sequencing sick molecules: diagnostic and therapeutic implications. 62nd National Congress of the Italian Biochemistry Society (SIB), September 9th, 2023. Florence, Italy (invited lecture).
9. SMaRT M-Seq: towards personalized medicine in monoclonal gammopathies. Amyloidosis Multidisciplinary Meeting – Memorial Sloan Kettering Cancer Center. June 16th, 2023. New York, USA (held online)(invited seminar)

10. La ricerca in biochimica clinica in Italia. 1st Course on Clinical Laboratory Medicine in the Era of Precision Medicine. International School of Precision Medicine and Laboratory Medicine. June 13th, 2023. Erice, Italy (round table)
11. How I treat AL amyloidosis. 4th How to diagnose and treat multiple myeloma. European Society of Hematology. April 16th, 2023. Berlin, Germany
12. Biomarkers to predict risk of AL amyloidosis. Intercepting Blood Cancer (IBC) 2023 Conference. Scheduled to be held on March 4th, 2023. Madrid, Spain (invited lecture).
13. Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies. 54th National Congress of the Italian Society of Clinical Chemistry and Clinical Molecular Biology. October 6th, 2022. Genoa, Italy (abstract selected for oral presentation).
14. Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies. XVIII International Symposium on Amyloidosis. September 5th, 2022, Heidelberg, Germany (abstract selected for oral presentation).
15. Biology of the amyloid plasma cell clone and implications for treatment. Course on Amyloidosis. Center of Excellence, Pavia Amyloidosis Research and Treatment Center. September 13th, 2022. Pavia, Italy (held online) (invited lecture).
16. Malattia clonale nell'amiloidosi AL: caratteristiche e implicazioni terapeutiche. FAD Sincrona "Amiloidosi & Mieloma Multiplo". November 25th, 2021. Online event.
17. Trattamento dell'amiloidosi AA. Common Grounds: From evidence based to real life Focus on new emerging targets in nephrology, dialysis and transplantation. November 11th, 2021. Bologna, Italy.
18. Biology of the amyloid plasma cell clone and implications for treatment. Course on Amyloidosis. Center of Excellence, Pavia Amyloidosis Research and Treatment Center. February 18th 2021. Pavia, Italy (held online)
19. AL amyloidosis: disease definition and biology. Master di I livello in management del Mieloma II parte. EMN Research Italy. July 10th 2020, Turin, Italy (held online)
20. Recent challenges in amyloidosis treatment. 57th ERA-EDTA Congress. June 6-9 2020, Milan, Italy (held online)
21. Targeting deubiquitylating enzymes USP14 and UCHL5 in systemic immunoglobulin light chain (AL) amyloidosis. XVII International Symposium on Amyloidosis. March 1-5 2020, Tarragona, Spain (held online)
22. Sick molecules and diseases. International School of Medical Sciences, 159th Course The value of laboratory medicine into clinical medicine. November 7-9 2019, Erice, Italy.
23. Harnessing proteotoxicity against AL amyloidosis. Annual meeting of the Italian Society of Amyloidosis, May 4th, 2019, Naples, Italy
24. Serum amyloid A and amyloidoses. 43rd Rheumatology Meeting, April 10th 2019, University of Padua, Padua, Italy
25. Update on AL amyloidosis. Hematology Debate 2019, Hematology Medical Education Forum, February 8th, 2019, Madrid, Spain
26. Workshop on Amyloidosis. Hematology Debate 2019, Hematology Medical Education Forum, February 7th, 2019, Madrid, Spain
27. Exploiting publicly available transcriptomic data sets for the selection of qPCR reference genes. 2^o Convegno Gruppo di Studio SIBioC Young Scientists, December 3rd, 2018, Rome, Italy
28. Harnessing proteotoxicity. Scientific retreat 2018, Foundation IRCCS Policlinico San Matteo, November 24th, 2018, Giussago, Italia
29. Targeting macrophages in amyloidosis. 1st Cuneo City immunotherapy Conference (CCITC) – Immunotherapy in hematological malignancies 2018 – May 18th, Cuneo, Italy.
30. Protein misfolding: the paradigm of AL amyloidosis. IV Workshop in Translational hematology, Società Italiana di Ematologia Sperimentale (SIES). November 17th, 2017. Parma, Italy.
31. Neurodegenerative disease proteins: prions or not? 5th Winter Seminar on Dementia and Neurodegenerative Disorders, Società Italiana di Neurologie per le Demenze (SINdem). January 20th, 2017. Brixen, Italy.
32. Prioni e demenze. Ticino Neuroscience Foundation. May, 19th 2016. Lugano, Switzerland.
33. Catene leggere libere e amiloidosi AL. Centro Europeo per la Formazione, l'Aggiornamento e la Ricerca in Scienze Sanitarie e in Biotecnologie (CEFAR). May, 9th 2016. Naples, Italy.
34. Modelli animali di amiloidosi AL. Annual meeting of the Italian Society of Amyloidosis. May, 9th 2015. Rome, Italy.
35. Generation of a conditional transgenic mouse model of immunoglobulin light chain (AL) amyloidosis. 15th Day of Clinical Research. March 31st, 2016. Zurich, Switzerland.
36. TALEN-based generation of a C57BL/6J mouse line lacking the cellular prion protein. Scuola Internazionale Superiore di Studi Avanzati (SISSA). March, 16th 2015. Trieste, Italy.

37. Amyloid formation and toxicity. 1st Symposium of the Amyloidosis Network Zürich. June 19th, 2014. Zurich, Switzerland
38. SIRPalpha polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells. Swiss Illumina User Day: "Advances in Genome Science: Next Generation Sequencing". Functional Genomic Center Zurich. February 11th, 2014. Zurich, Switzerland
39. Work package 7: "Implementation of biomarker monitoring in rapid progressive Dementia / Prion". Joint Programming Neurodegenerative Disease: "Biomarker based diagnosis of rapid progressive dementias – optimization of diagnostic protocols – DemTest". September 05th, 2013. Barcelona, Spain
40. Work package 4: "What is the function of PrP^C?". PRIORITY, FP7- 222887 "Protecting the food chain from prions: Shaping European priorities through basic and applied research". January 31st, 2013. Brussels, Belgium
41. Work package 4: "What is the function of PrP^C?". PRIORITY, FP7-222887 "Protecting the food chain from prions: Shaping European priorities through basic and applied research". June 25th, 2012. SISSA, Scuola Internazionale Superiore di Studi Avanzati, Trieste, Italy
42. Prion protein and A β -related synaptic toxicity impairment. PRIORITY, FP7-222887 "Protecting the food chain from prions: Shaping European priorities through basic and applied research". November 1st, 2010, University Hospital of Zurich, Zurich, Switzerland
43. *Prnp* and *Sirpa*: a dangerous liaison. 11th day of clinical research. April 19th, 2012. Zurich, Switzerland
44. Prion replication in mice harbouring a human hemato-lymphoid system. III International Symposium on the new prion biology: basic science, diagnosis and therapy. April 2nd-4th, 2009. Venice, Italy
45. Prognostic relevance of serum N-terminal natriuretic peptide type B and cardiac Troponin I in patients with AL amyloidosis. 38th National Congress of the Italian Society of Clinical Chemistry and Clinical Molecular Biology. September 19th-22nd, 2006. Turin, Italy

Il sottoscritto, consapevole che – ai sensi dell'art. 76 del D.P.R. 445/2000 – le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali, dichiara che le informazioni rispondono a verità.

Il sottoscritto dichiara di aver ricevuto l'informativa sul trattamento dei dati personali, pubblicata al seguente link: <https://privacy.unipv.it>.

Il sottoscritto è consapevole che il presente documento potrebbe essere oggetto di pubblicazione per finalità di trasparenza sul sito web dell'Università degli Studi di Pavia.

Pavia, 27/12/2023